Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
Foghorn Therapeutics(US:FHTX) Newsfilter·2024-03-07 12:00• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 • FHD-909, a first-in-class BRM selective inhibitor, selected for clinical development by partner Lilly; preclinical data to be presented at AACR with IND planned for the second quarter, primary target patient population in non-small cell lung cancer • Selective CBP and EP300 degrader preclinical data to be presented at AACR; IND-enabling studies for CBP degrader program planned ...